Wang Yang emphasized
Private enterprises are an indispensable force driving economic and social development. All localities and departments should actively listen to the voices of enterprises, pay attention to their demands, further enhance service awareness, strengthen resource guarantees, continuously optimize the business environment, and fully assist enterprises in addressing difficulties and challenges. Efforts should be made to create a strong atmosphere supportive of private enterprise development, promoting the healthy development of the private economy.
Private enterprises should maintain confidence in development, grasp the overall trend of development, actively explore markets, fully leverage their technological advantages, make good use of various policies, strive to secure orders, stabilize development, further consolidate future development prospects, promote quality and efficiency improvement, and cultivate and strengthen new growth points. This will contribute significantly to the high-quality development of the regional economy.
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Established in 1994, Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. was listed on the main board of the Shanghai Stock Exchange in 1999. It is a high-tech and growing listed company primarily engaged in pharmaceuticals, medical aesthetics, investments, and other industries. The company has an integrated pharmaceutical industry chain covering research and development, production, and sales. Currently, the company is advancing the construction of the Jiangsu Wuzhong Pharmaceutical Research and Industrialization Base, aiming to become a leading modern pharmaceutical experimental research, pilot-scale research, and large-scale production base. This initiative will meet the needs of developing new businesses such as CDMO and medical aesthetics products, laying a foundation for comprehensive industrial upgrading.
During the visit, Wang Yang and his delegation first visited Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. They inspected the company's laboratories, warehouses, and other areas, engaging in in-depth discussions with relevant company officials to gain detailed insights into the company's main products, resumption of work and production, construction of production bases, and automated warehousing systems. Wang emphasized the importance of seizing development opportunities, integrating advantageous resources, continuously improving the quality of generic drugs, accelerating the pace of innovative drug research and development, enhancing digital management capabilities, and striving to become a vanguard in the pharmaceutical industry's development.
Ecovacs Robotics Co., Ltd.
Established in 1998, Ecovacs Robotics Co., Ltd. has evolved into a group-type international brand company with key core technologies, high-end brands "ECOVACS" and "TINECO," as well as a complete product line and industry chain. The company went public on the A-share main board of the Shanghai Stock Exchange in 2018, becoming the first listed company in the domestic "service robot" sector. The company continues to increase its investment in research and development and currently has over 1,200 R&D personnel. As of December 2022, the company has led and participated in the formulation of 34 international, national, industry, and group standards and has accumulated a total of 1,566 authorized patents at home and abroad.
During the visit to Ecovacs Robotics Co., Ltd., Wang Yang and his delegation visited the company's exhibition hall, inspected products, inquired about innovation, and discussed challenges, gaining insights into the company's development history, product types, market share, and future plans. Wang commended the company's positive development momentum and encouraged it to seize opportunities, strengthen research and development efforts, fully promote product iteration and category innovation, actively expand cooperation with industry associations, pioneer new frontiers in smart home appliances, and consistently focus on product quality, scale, and brand influence.
Suzhou CORNIGS Polyol Co., Ltd.
Established in 2018, Suzhou CORNIGS Polyol Co., Ltd. is the first domestic high-tech enterprise in China to utilize biomanufacturing methods for the research, development, production, and application of bio-based materials and bio-based polymers. The company has constructed the first GMP-standard automated production line for plant-based polyols in China and has jointly established a research and development center with Nanjing Tech University. Additionally, it collaborates with Shenzhen University and Peking University, and has established a world-class biological development laboratory. The company's bio-based polyol products have entered the global supply chains of dozens of Fortune 500 customers, including BASF in Germany, DuPont in the United States, and Fuji in Japan.
During the visit to Suzhou CORNIGS Polyol Co., Ltd., Wang Yang and his delegation received an introduction from the company's leaders on aspects such as product line layout, application fields, intellectual property rights, and development strategies. They also inquired earnestly about production operations, financing needs, and industry-university-research cooperation. Wang encouraged the company to deepen its expertise in its professional field, continuously break through integrated technological barriers from key technologies to core processes, enhance product competitiveness, broaden market space and sales channels, and provide support for the company's steady and far-reaching development.
